TREACE MEDICAL CONCEPTS, INC.
No enriched coverage for $TMCI in the last 7 days.
Treace John T. (Chief Executive Officer) purchased 55,944 shares of TREACE MEDICAL CONCEPTS, INC. (TMCI) at an average of $4.41 ($4.34–$4.44, $0.25M total) across 3 trades over 2026-08-20 to 2026-08-24.
Treace Medical Concepts reported Q2 2026 earnings call updates. Management cited higher case volumes and surgeon adoption of its bunion portfolio for sequential revenue growth, while YoY revenue fell due to lower kit sales to stocking distributors and mix shift to lower-priced minimally invasive products. Full-year 2026 revenue guidance was raised to $204M to $212M, with expectations for reduced cash usage and improved adjusted EBITDA leverage.
Treace Medical Concepts (NasdaqGS: TMCI) reported Q2 2026 revenue of $45.4 million, down from $47.4 million in Q2 2025, with a net loss of $15.9 million and adjusted EBITDA loss of $3.5 million. Cash usage year to date fell 57% to $3.6 million, with $45.6 million cash and securities at June 30. The company raised 2026 revenue guidance to $204-$212 million and expects adjusted EBITDA loss of $3.0-$5.0 million.
Recent TMCI coverage spans insider activity, earnings and market movers.
In the last 30 days, TMCI insiders filed 3 SEC Form 4 transactions — 3 purchases ($247K) and no sales. The most active reporter was Treace John T., Chief Executive Officer, with 3 filings.
Insider purchase signals confidence, may support short-term price stability.
Treace Medical Concepts reported Q2 2026 earnings call updates. Management cited higher case volumes and surgeon adoption of its bunion portfolio for sequential revenue growth, while YoY revenue fell due to lower kit sales to stocking distributors and mix shift to lower-priced minimally invasive products. Full-year 2026 revenue guidance was raised to $204M to $212M, with expectations for reduced cash usage and improved adjusted EBITDA leverage.
Guidance raise with tighter Adjusted EBITDA loss range and reduced cash burn improves downside risk versus prior outlook.
Guidance upgrade plus improved cash burn and expense reductions suggest improving operating leverage, but revenue still slightly down YoY.
Device milestone completion plus commercialization timing can drive incremental optimism, but impact is likely smaller without revenue guidance changes.
alphai scores every news story that mentions TMCI with an AI model for sentiment and relevance, and aggregates insider trades from TREACE MEDICAL CONCEPTS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Treace John T. (Chief Executive Officer) purchased 55,944 shares of TREACE MEDICAL CONCEPTS, INC. (TMCI) at an average of $4.41 ($4.34–$4.44, $0.25M total) across 3 trades over 2026-08-20 to 2026-08-24.
1 min readTreace Medical Concepts reported Q2 2026 earnings call updates. Management cited higher case volumes and surgeon adoption of its bunion portfolio for sequential revenue growth, while YoY revenue fell due to lower kit sales to stocking distributors and mix shift to lower-priced minimally invasive products. Full-year 2026 revenue guidance was raised to $204M to $212M, with expectations for reduced cash usage and improved adjusted EBITDA leverage.
6 min readTreace Medical Concepts (NasdaqGS: TMCI) reported Q2 2026 revenue of $45.4 million, down from $47.4 million in Q2 2025, with a net loss of $15.9 million and adjusted EBITDA loss of $3.5 million. Cash usage year to date fell 57% to $3.6 million, with $45.6 million cash and securities at June 30. The company raised 2026 revenue guidance to $204-$212 million and expects adjusted EBITDA loss of $3.0-$5.0 million.
4 min readTREACE MEDICAL CONCEPTS, INC. (TMCI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2026 Financial Results PONTE VEDRA, Fla. – August 7, 2026 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment o
6 min readBoundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
7 min readTreace John T. (Chief Executive Officer) purchased 24,606 shares of TREACE MEDICAL CONCEPTS, INC. (TMCI) at an average of $4.03 ($4.02–$4.04) across 2 trades over 2026-06-10 to 2026-06-11.
1 min readTreace John T. (Chief Executive Officer) purchased 52,317 shares of TREACE MEDICAL CONCEPTS, INC. (TMCI) at an average of $4.03 ($4.02–$4.04, $0.21M total) across 2 trades over 2026-06-10 to 2026-06-11.
1 min readBiotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.
7 min readTreace John T. (Chief Executive Officer) purchased 50,000 shares of TREACE MEDICAL CONCEPTS, INC. (TMCI) at $3.56 ($0.18M total) on 2026-06-01.
3 min readTreace John T. (Chief Executive Officer) purchased 115,520 shares of TREACE MEDICAL CONCEPTS, INC. (TMCI) at an average of $2.95 ($2.79–$3.02, $0.34M total) across 3 trades over 2026-05-26 to 2026-05-28.
2 min read